In Brief This Week: Epigenomics; Chronix Biomedical; Source Bioscience, Illumina; Genewiz; CambridgeSoft, VIB; Isilon Systems, TGen; and More | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics said this week that updated study data on its Septin9 biomarker had detected colorectal cancer cases with a sensitivity of 63 percent and specificity of around 89 percent. The German molecular diagnostics firm said that the results meet the targeted specificity range of 85 percent to 90 percent, which should support public and private payer coverage and reimbursement. The results met the firm's primary study objective.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.